Biotechnology

Overview

Our Biotechnology group has been serving clients in patent prosecution for nearly 30 years. Our team of more than 20 attorneys, the majority of whom have M.Sc., Ph.D., and graduate degrees, includes experienced scientists, skilled engineers, and accomplished patent agents. Their extensive knowledge of Life Science disciplines provides a deep understanding of our clients’ needs in this arena.

Notably, Honigman was recently awarded the Managing Intellectual Property “U.S. – Firm to Watch” in 2020. We were also named Intellectual Property “Firm to Watch” by LMG Life Sciences in 2016 and made the “Firm to Watch” shortlist in 2019.

We have a broad range of experience with global pharmaceutical and biotechnology IP related procedures, patent filings, and regulatory requirements. Clients benefit from our demonstrated knowledge of pharmaceutical, biotechnology, medical device global patent post-grant proceedings and litigation. We have developed and implemented global IP patent procurement strategies for FDA approved medicines, IP strategic planning, studies on patentability, infringement and validity, IP audits and due diligence, licensing and technology transfer. 

Our patent attorneys routinely assist clients with freedom to operate and competitor analyses for a wide range of pharmaceutical and biotechnology small and large molecule drug therapies. In addition, because our team is highly integrated with the firm’s corporate, litigation, and transactional practices, we provide value by efficiently delivering services while containing costs. We strive to exceed our client’s expectations in service delivery standards, communication, and consistent results.